Ceftaroline

In vitro antimicrobial activities of 7 agents against 56 PNSP isolates were examined. For this purpose, MICs of the bacterial strains were determined using MIC Test Strips (Liofilchem S.r.l., Roseto, Italy). Testing was executed as specified by the manufacturer. With the test strips, MICs between 0.002 µg/mL and 32 µg/mL could be evaluated. Seven antimicrobials were tested: ceftaroline (Allergan, Dublin, Ireland), ceftobiprole (Basilea Pharmaceutica, Basel, Switzerland), dalbavancin (Durata Therapeutics Holding, Morristown, NJ, USA), delafloxacin (Melinta Therapeutics, New Haven, CT, USA), eravacycline (Tetraphase Pharmaceuticals, Watertown, NY, USA), tedizolid (Merck Sharp & Dohme Corp., Kenilworth, NJ, USA) and telavancin (Astellas Pharma US, Chūō, Japan). Out of these 7 antimicrobials, EUCAST clinical breakpoints for S. pneumoniae are currently available only for ceftaroline (0.25 µg/mL) and ceftobiprole (0.5 µg/mL).5 The Clinical and Laboratory Standards Institute (CLSI) defines the susceptibility breakpoint for ceftaroline and S. pneumoniae at 0.5 µg/mL.12 For MIC interpretation EUCAST breakpoints were used; however, using CLSI breakpoints would not have affected the interpretation of the results.